from BIOMERIEUX (EPA:BIM)
bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D
bioMérieux announces nomination
of two new Executive Committee members to lead Medical Affairs and R&D
Marcy-l’Étoile, France – January 16th, 2024 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the appointment of two new Executive Committee members:
• Dr. Charles K. Cooper as Executive Vice President, Chief Medical Officer, effective January 2nd, 2024;
• Céline Roger-Dalbert as Executive Vice President Research and
Development, effective March 1st, 2024.
Dr. Charles K. Cooper succeeds Dr. Mark Miller, as Executive Vice President, Chief Medical Officer, effective January 2nd, 2024.
Dr. Charles K. Cooper is a graduate from Georgetown University School of Medicine (Washington, DC) and specialized in infectious diseases and epidemiology (University of Maryland, Baltimore). He has been practicing medicine for over 25 years and still devotes two days a month to this work.
He was previously Chief Medical Officer at Siemens Healthcare Diagnostics. He also spent 8 years at Becton Dickinson and 13 years with the U.S. Food & Drug Administration. With this extensive experience in both governmental and private organizations, Dr. Charles K. Cooper will be a major asset for bioMérieux to address its global patients and customers’ needs, helping improve public health worldwide.
Céline Roger-Dalbert will succeed François Lacoste, as Executive Vice President Research & Development effective March 1st, 2024.
Céline Roger-Dalbert joined bioMérieux in August 2022 as Senior Vice President, R&D Clinical and Regulatory Affairs.
She earned a Master’s Degree in Biotechnology from the Lyon
Catholic University, France. She began her career holding various
management roles for bioMérieux in R&D Microbiology. Then, she spent 15 years at Becton Dickinson as Vice President of R&D and Program Management, in Molecular, Microbiology and Point-of-Care Diagnostics in Canada and the U.S. Through her more than 25 years of in vitro diagnostic experience, she has been involved in more than 30 new product launches, including new or innovative technologies and contributing to delivering diffenciated solutions improving clinical outcomes. She is also the co-inventor of more than 20 patent applications. Céline Roger-Dalbert will lead R&D and drive innovation, one of the pillars of bioMérieux’s strategy.
Dr. Mark Miller and François Lacoste are both retiring after years of exemplary collaboration with bioMérieux. They have played a pivotal role in the success of the Company and bioMérieux thanks them warmly for their commitment.
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2022, revenues reached €3.6 billion, with over 90% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. www.biomerieux.com.
bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
CONTACTS
Investor Relations
Aymeric Fichet
Tel.: +33 (0)4 78 87 20 00 investor.relations@biomerieux.com
Media Relations
Corporate France United States
Romain Duchez Claire Doligez (Image 7) Liza Deckelbaum (SEEZ)
Tel.: +33 (0)4 78 87 21 99 Tel.: +33 (0)1 53 70 74 48 919.645.0782 media@biomerieux.com cdoligez@image7.fr lizad@seeztoday.com